Osmol is a clinical stage biopharma company developing a first-in-class preventative treatment (OSM-0205) for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a significant unmet need associated with microtubule-based chemotherapies such as taxanes, the most widely used breast cancer chemotherapy treatment. CIPN can be both debilitating and effect cancer treatment outcomes. There are no approved treatments for CIPN, leaving patients’ only option to reduce their chemotherapy treatment (dose or duration). Osmol’s initial focus is in breast cancer where up to 80% of taxane treated patients develop CIPN and 50% have their treatment reduced. The FDA notified Osmol our Phase 1 clinical study may proceed. Market research with breast cancer specialists at leading US cancer centers and payers covering 100M US lives confirmed the significant need for OSM-0205 and it would be reimbursed. OSM-0205 peak sales for taxane-treated patients alone is projected to exceed $1.2B (US and EU).